EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news
Issue link: https://daily.eyeworld.org/i/124062
NEW ILEVRO™ Suspension Designed to put potency precisely where you need it 1,2 ONCE-DAILY POST-OP One drop should be applied once daily beginning 1 day prior to surgery through 14 days post-surgery, with an additional drop administered 30 to 120 minutes prior to surgery 3 Use of ILEVRO™ Suspension more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events3 INDICATIONS AND USAGE ILEVRO™ Suspension is a nonsteroidal, anti-infammatory prodrug indicated for the treatment of pain and infammation associated with cataract surgery. Dosage and Administration One drop of ILEVRO™ Suspension should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the frst 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. IMPORTANT SAFETY INFORMATION Contraindications ILEVRO™ Suspension is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other NSAIDs. Warnings and Precautions tODSFBTFE#MFFEJOH5JNFo8JUITPNFOPOTUFSPJEBMBOUJJOý * BNNBUPSZ drugs including ILEVRO™ Suspension there exists the potential for increased bleeding time. Ocularly applied nonsteroidal anti-infammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. t FMBZFE)FBMJOHo5PQJDBMOPOTUFSPJEBMBOUJJOý % BNNBUPSZESVHT/4"*%T including ILEVRO™ Suspension may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. t PSOFBM&GGFDUTo6TFPGUPQJDBM/4"*%TNBZSFTVMUJOLFSBUJUJT*OTPNF $ patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. 5IFTFFWFOUTNBZCFTJHIUUISFBUFOJOH1BUJFOUTXJUIFWJEFODFPGDPSOFBM epithelial breakdown should immediately discontinue use. ©2013 Novartis 2/13 NPF12014JAD BUJFOUTXJUIDPNQMJDBUFEPDVMBSTVSHFSJFT DPSOFBMEFOFSWBUJPO DPSOFBM 1 epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which NBZCFDPNFTJHIUUISFBUFOJOH5PQJDBM/4"*%TTIPVMECFVTFEXJUI caution in these patients. TFNPSFUIBOEBZQSJPSUPTVSHFSZPSVTFCFZPOEEBZTQPTUTVSHFSZ 6 may increase patient risk and severity of corneal adverse events. t POUBDU-FOT8FBSo*-&730™ Suspension should not be administered $ while using contact lenses. Adverse Reactions 5IFNPTUGSFRVFOUMZSFQPSUFEPDVMBSBEWFSTFSFBDUJPOTGPMMPXJOHDBUBSBDU surgery occurring in approximately 5 to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. For additional information about ILEVRO™ Suspension, please refer to the brief summary of prescribing information on adjacent page. References: 1. Ke T-L, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation, II: In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24(4):371-384. 2. Data on file. 3. ILEVRO™ Suspension package insert.